Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors in the central anxious procedure, conolidine modulates alternate molecular targets. A Science Developments review observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://bobu330kxl6.goabroadblog.com/profile